drugset / Trial / NCT01689740

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

NCT01689740 ↗

Phase 2 Completed 10 enrolled Resilient Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD. The main question it aims to answer is: Is there a reduction in PTSD symptoms in people given a low dose of MDMA with therapy versus a high dose of MDMA with therapy? Researchers will compare two sessions of MDMA-assisted therapy with either 25 mg of MDMA HCl or 125 mg of MDMA HCl in Stage 1. Participants will undergo preparatory therapy sessions without any study drug, followed by two sessions of MDMA-assisted therapy, each followed by integrative therapy sessions without study drug. Participants who received 25 mg during Stage 1 will be given the option to enroll in Stage 2 and complete two additional open-label MDMA-assisted therapy sessions with the full dose of 125 mg MDMA.

Timeline

Start
2013-01-17
Primary completion
2016-04-07
Completion
2017-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject MDMA Unknown 25 mg Oral
Subject MDMA Unknown 125 mg Oral